The recent ruling (21 November 2018) of the European Court of Justice puts an end to the dispute over the off-label use of bevacizumab for age-related macular degeneration.
Perspectives
Focus on
Indications for medical useTetrahydrocannabinol (THC) and cannabidiol (CBD) are the main active substances of cannabis sativa and among the pharmacological targets have both cannabinoid receptors (CB1 and CB2), the peptide receptor related to the calcitonin gene, the ligand dependent ion channels...
Columns
Phytovigilance & Supplements
IntroductionSince 2002, the Italian National Institute of Health (ISS) has coordinated the national phyto-vigilance system.1 This system is based on the collection and evaluation of spontaneous reports of suspected adverse reactions that have occurred after taking food supplements, vitamins,...
From regulatory agencies
| 24 January 2020 FDA | 23 January 2020 FDA |
| 23 January 2020 FDA | 16 January 2020 FDA |
| 16 January 2020 FDA | 15 January 2020 FDA |
| 14 January 2020 FDA | 13 January 2020 FDA |
| 13 January 2020 FDA | 13 January 2020 FDA |